Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M., Pastan, I., & Willingham, M. (1987) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.84.21.7735 · Cited by 2,823

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians

Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Kim, R. B., Fromm, M. F., Wandel, C., Leake, B. F., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 855

Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P. G., Wolff, T., & Waxman, D. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)89213-x · Cited by 724

Human P-glycoprotein transports cyclosporin A and FK506.

Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53221-x · Cited by 684

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*

Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin‐Ren, P., Brown, M. B., Guo, W.-S., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 679

Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.

Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T., & Hori, R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35757-0 · Cited by 672

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortlage, L. A., Brown, M. B., Guo, W., & Watkins, P. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119439 · Cited by 624

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*

Thummel, K. E., O’Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 615

Enterohepatic Circulation

Roberts, M. S., Magnusson, B. M., Burczynski, F. J., & Weiß, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00005 · Cited by 684

Inhibition and induction of human cytochrome P450 enzymes: current status

Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 571

Cytochrome P450-mediated metabolism in the human gut wall

Thelen, K., & Dressman, J. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.05.0002 · Cited by 338

Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

Varma, M. V. S., Obach, R. S., Rotter, C. J., Miller, H., Chang, G., Steyn, S. J., El‐Kattan, A. F., & Troutman, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901371v · Cited by 349

Gut reactions: Breaking down xenobiotic–microbiome interactions

Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

Gertz, M., Harrison, A., Houston, J., & Galetin, A. (2010) · Drug Metabolism And Disposition · doi:10.1124/dmd.110.032649 · Cited by 317

Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants

Saad, A. H., DePestel, D. D., & Carver, P. L. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.12.1730 · Cited by 295

The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates

Cotreau, M. M., Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 291

Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4

Cummins, C. L., Jacobsen, W., & Benet, L. Z. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1036 · Cited by 289

P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine

Mouly, S. J., & Paine, M. F. (2003) · Pharmaceutical Research · doi:10.1023/a:1026183200740 · Cited by 276

Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism

van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M. M., van Waterschoot, R. A. B., Smit, J. W., Song, J.-Y., van der Valk, M. A., van Tellingen, O., van der Hoorn, J. W. A., Rosing, H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33435 · Cited by 235

Dietary Effects on Drug Metabolism and Transport

Harris, R. Z., Jang, G. R., & Tsunoda, S. M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00001 · Cited by 217

DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1

Chen, C., Mireles, R. J., Campbell, S. D., Lin, J., Mills, J. B., Xu, J. J., & Smolarek, T. A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002477 · Cited by 210

Interactions between CYP3A4 and Dietary Polyphenols

Basheer, L., & Kerem, Z. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/854015 · Cited by 204

Loss of orally administered drugs in GI tract

Gavhane, Y. N., & Yadav, A. V. (2012) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2012.03.005 · Cited by 164

PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION

Galetin, A., Burt, H. J., Gibbons, L. E., & Houston, J. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006874 · Cited by 160

Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

Galetin, A., & Houston, J. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106013 · Cited by 155

Immunoquantitation of FMO1 in Human Liver, Kidney, and Intestine

Yeung, C. K., Lang, D. H., Thummel, K. E., & Rettie, A. E. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15194-x · Cited by 130

Down-Regulation of Intestinal Drug Transporters in Chronic Renal Failure in Rats

Naud, J., Michaud, J., Boisvert, C., Desbiens, K., Leblond, F. A., Mitchell, A., Jones, C., Bonnardeaux, A., & Pichette, V. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112631 · Cited by 126

Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort?

Mouly, S. J., Lloret‐Linares, C., Sellier, P., Sène, D., & Bergmann, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.038 · Cited by 130

Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

Galetin, A., Gertz, M., & Houston, J. B. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.909 · Cited by 124

Hepatic drug metabolism and transport in patients with kidney disease

Nolin, T. D., Frye, R. F., & Matzke, G. R. (2003) · American Journal of Kidney Diseases · doi:10.1016/j.ajkd.2003.07.019 · Cited by 116

Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions

Galetin, A., Gertz, M., & Houston, J. B. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.28 · Cited by 113

Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs

Yamreudeewong, W., DeBisschop, M., Martin, L. G., & Lower, D. L. (2003) · Drug Safety · doi:10.2165/00002018-200326060-00004 · Cited by 106

Enaminones: Exploring Additional Therapeutic Activities

Edafiogho, I. O., Kombian, S. B., Ananthalakshmi, K. V. V., Salama, N. N., Eddington, N. D., Wilson, T. L., Alexander, M. S., Jackson, P. L., Hanson, C. D., & Scott, K. R. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20967 · Cited by 107

Cytochrome P4503APolymorphisms and Immunosuppressive Drugs: An Update

Anglicheau, D., Legendre, C. M., Beaune, P. H., & Thervet, É. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.835 · Cited by 93

A New Physiologically Based, Segregated-Flow Model to Explain Route-Dependent Intestinal Metabolism

Cong, D. H. T. N. Q., Doherty, M., & Pang, K. S. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15132-x · Cited by 90

Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients

Qiu, X., Jiao, Z., Zhang, M., Zhong, L.-J., Hui-qi, L., Ma, C.-L., Zhang, L., & Zhong, M. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0520-8 · Cited by 89

In Vitro Flow Cytometry Method to Quantitatively Assess Inhibitors of P-Glycoprotein

Wang, E., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15095-7 · Cited by 87

The Role of P-Glycoprotein and Organic Anion-Transporting Polypeptides in Drug Interactions

DuBuske, L. M. (2005) · Drug Safety · doi:10.2165/00002018-200528090-00004 · Cited by 84

Midazolam Exhibits Characteristics of a Highly Permeable P-Glycoprotein Substrate

Tolle‐Sander, S., Rautio, J., Wring, S., Polli, J. W., & Polli, J. E. (2003) · Pharmaceutical Research · doi:10.1023/a:1023433502647 · Cited by 81

Drug interactions during therapy with three major groups of antimicrobial agents

Shakeri‐Nejad, K., & Stahlmann, R. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.639 · Cited by 77

The Evolving Role of Drug Metabolism in Drug Discovery and Development

Yengi, L. G., Leung, L. Y., & Kao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9217-9 · Cited by 76

In Vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance

Strelevitz, T. J., Foti, R., & Fisher, M. B. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20538 · Cited by 73

Toxicological hazard induced by sucralose to environmentally relevant concentrations in common carp (Cyprinus carpio)

Saucedo-Vence, K., Elizalde‐Velázquez, A., Dublán‐García, O., Galar‐Martínez, M., Islas‐Flores, H., SanJuan‐Reyes, N., García-Medina, S., Hernández‐Navarro, M. D., & Gómez‐Oliván, L. M. (2016) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2016.09.230 · Cited by 64

Drug interactions in transplant patients: what everyone should know

Manitpisitkul, W., McCann, E. J., Lee, S., & Weir, M. R. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32832edcb2 · Cited by 63

Induction of Multidrug Resistance-1 and Cytochrome P450 mRNAs in Human Mononuclear Cells by Rifampin

Asghar, A., Gorski, J. C., HAEHNERDANIELS, B., & Hall, S. D. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.1.20 · Cited by 61

Screening of Genetic Polymorphisms ofCYP3A4andCYP3A5Genes

Lee, J. S., Cheong, H. S., Kim, L. H., Kim, J. O., Seo, D. W., Kim, Y., Chung, M. W., Han, S. Y., & Shin, H. D. (2013) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2013.17.6.479 · Cited by 60

Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4

Mouly, S. J., Meune, C., & Bergmann, J. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1384-1 · Cited by 55

How important is intestinal cytochrome P450 3A metabolism?

van Herwaarden, A. E., van Waterschoot, R. A. B., & Schinkel, A. H. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.02.003 · Cited by 54

Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis

Shi, X., Geng, F., Jiao, Z., Cui, X.-Y., Qiu, X., & Zhong, M. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01206.x · Cited by 52

Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications

Stockmann, C. R., Constance, J. E., Roberts, J. K., Olson, J. A., Doby, E. H., Ampofo, K., Stiers, J., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0139-0 · Cited by 51

Route-Dependent Metabolism of Morphine in the Vascularly Perfused Rat Small Intestine Preparation

Doherty, M. M., & Pang, K. S. (2000) · Pharmaceutical Research · doi:10.1023/a:1007548905772 · Cited by 46

Transdermal delivery of drugs for urologic applications: Basic principles and applications

Νitti, V. W., Sanders, S., Staskin, D. R., Dmochowski, R. R., Sand, P. K., MacDiarmid, S., & Maïbach, H. I. (2006) · Urology · doi:10.1016/j.urology.2005.11.039 · Cited by 45

Rhabdomyolysis and Acute Renal Failure in a Cardiac Transplant Recipient due to Multiple Drug Interactions

Kusus, M., Stapleton, D. D., Lertora, J. J. L., Simon, E. E., & Dreisbach, A. W. (2000) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200012000-00007 · Cited by 43

Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery

Davies, M., Peramuhendige, P., King, L. M., Golding, M., Kotian, A., Penney, M., Shah, S. A. B., & Manevski, N. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000111 · Cited by 34

Modeling Enterohepatic Circulation

Okour, M., & Brundage, R. C. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0096-z · Cited by 33

Glucuronidation of the Dietary Fatty Acids, Phytanic Acid and Docosahexaenoic Acid, by Human UDP-Glucuronosyltransferases

Little, J. M., Williams, L., Xu, J. B., & Radominska-p, A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.531 · Cited by 32

Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers

Ridtitid, W., Ratsamemonthon, K., Mahatthanatrakul, W., & Wongnawa, M. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00862.x · Cited by 32

Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans

Videau, O., Delaforge, M., Levi, M., Thévenot, E., Gal, O., Becquemont, L., Beaune, P. H., & Bénech, H. (2010) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4641 · Cited by 30

Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver

Kato, K., Ohbuchi, M., Hamamura, S., Ohshita, H., Kazuki, Y., Oshimura, M., Sato, K., Nakada, N., Kawamura, A., Usui, T., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.063479 · Cited by 29

The Pharmacogenetics of Immunosuppression for Organ Transplantation

Fredericks, S., Holt, D. W., & MacPhee, I. A. M. (2003) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200303050-00001 · Cited by 28

Advancing understanding of human variability through toxicokinetic modeling, in vitro-in vivo extrapolation, and new approach methodologies

Kreutz, A., Chang, X., Högberg, H. T., & Wetmore, B. A. (2024) · Human Genomics · doi:10.1186/s40246-024-00691-9 · Cited by 27

Polymer-surfactant nanoparticles for improving oral bioavailability of doxorubicin

Kirtane, A. R., Narayan, P., Liu, G., & Panyam, J. (2016) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-016-0293-5 · Cited by 27

Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism

Watanabe, H., Sugimoto, R., Ikegami, K., Enoki, Y., Imafuku, T., Fujimura, R., Bi, J., Nishida, K., Sakaguchi, Y., Murata, M., et al. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.016 · Cited by 27

Modulation of P450 CYP3A4-Dependent Metabolism by P-glycoprotein: Implications for P450 Phenotyping

Baron, J. M., Goh, L. B., Yao, D., Wolf, C. R., & Friedberg, T. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38742-7 · Cited by 26

Pharmacokinetics and Disposition of Silodosin (KMD-3213)

MATSUBARA, Y., KANAZAWA, T., Kojima, Y., Abe, Y., Kobayashi, K., Kanbe, H., HARADA, H., Momose, Y., TERAKADO, S., Adachi, Y., et al. (2006) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.126.237 · Cited by 25

Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole

Seidegård, J., Nyberg, L., & Borgå, O. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.07.005 · Cited by 25

Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test

Lemahieu, W. P. D., Maes, B., Ghoos, Y. F., Rutgeerts, P., Verbeke, K., & Vanrenterghem, Y. F. C. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00028.2003 · Cited by 25

Contribution of Rat Pulmonary Metabolism to the Elimination of Lidocaine, Midazolam, and Nifedipine

Aoki, M., Okudaira, K., Haga, M., Nishigaki, R., & Hayashi, M. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032227 · Cited by 23

Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients

Qiu, F., Xiao-jing, H., Sun, Y., Li‐Ling, J., & Zhao, L. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70594-1 · Cited by 22

An update on the use of transdermal oxybutynin in the management of overactive bladder disorder

Cohn, J. A., Brown, E. T., Reynolds, W. M., Kaufman, M. R., Milam, D. F., & Dmochowski, R. R. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287215626312 · Cited by 22

Managing drug interactions in the patient with aspergillosis

Lewis, R. E. (2006) · Medical Mycology · doi:10.1080/13693780600835724 · Cited by 21

Interactions médicaments–aliments en médecine interne : quels messages pour le clinicien ?

Mouly, S. J., Morgand, M., Lopes, A., Lloret‐Linares, C., & Bergmann, J. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.12.010 · Cited by 22

Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor

Kammerer, B., Scheible, H., Albrecht, W., Gleiter, C. H., & Laufer, S. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013409 · Cited by 20

Explorations into modeling human oral bioavailability

Wang, Z., Yan, A., Yuan, Q., & Gasteiger, J. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.05.017 · Cited by 19

In Vitro–In Vivo Inaccuracy: The CYP3A4 Anomaly

Bowman, C. M., & Benet, L. Z. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.088427 · Cited by 18

Differentiation of Gut and Hepatic First-Pass Effect of Drugs: 1. Studies of Verapamil in Ported Dogs

Lee, Y.-H., Perry, B. A., Lee, H., Kunta, J. R., Sutyak, J. P., & Sinko, P. J. (2001) · Pharmaceutical Research · doi:10.1023/a:1013374630274 · Cited by 18

Remofovir Mesylate: A Prodrug of PMEA with Improved Liver-Targeting and Safety in Rats and Monkeys

Lin, C., Yeh, L., Vitarella, D., Hong, Z., & Erion, M. D. (2004) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020401500603 · Cited by 18

Sex-dependent expression of CYP2C11 in spleen, thymus and bone marrow regulated by growth hormone

Thangavel, C., Dhir, R. N., Volgin, D. V., & Shapiro, B. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.035 · Cited by 15

In Vitro Techniques to Study Drug–Drug Interactions of Drug Metabolism: Cytochrome P450

Houston, J. B., & Galetin, A. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0840-7_7 · Cited by 13

Basolateral and canalicular transport of xenobiotics in the hepatocyte: A review

Díaz, G. J. (2000) · Cytotechnology · doi:10.1023/a:1008152205697 · Cited by 13

AUTOINDUCTION OF MKC-963 [(R)-1-(1-CYCLOHEXYLETHYLAMINO)-4-PHENYLPHTHALAZINE] METABOLISM IN HEALTHY VOLUNTEERS AND ITS RETROSPECTIVE EVALUATION USING PRIMARY HUMAN HEPATOCYTES AND CDNA-EXPRESSED ENZYMES

Shimizu, T., Akimoto, K., Yoshimura, T., Niwa, T., Kobayashi, K., Tsunoo, M., & Chiba, K. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007997 · Cited by 13

The Role of Sulfotransferases (SULTs) and UDP-Glucuronosyltransferases (UGTs) in Human Drug Clearance and Bioactivation

Coughtrie, M. W. H., & Fisher, M. (2003) · Informa Healthcare eBooks · doi:10.1201/9781420028485.ch15 · Cited by 13

Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion

Brown, K. C., & Kashuba, A. D. M. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-213-7_2 · Cited by 12

Upholding or Breaking the Law of Superposition in Pharmacokinetics

Yousef, M., Yáñez, J. A., Löbenberg, R., & Davies, N. M. (2024) · Biomedicines · doi:10.3390/biomedicines12081843 · Cited by 10

Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation

Tapirdamaz, Ö., Hesselink, D. A., Bouazzaoui, S. E., Azimpour, M., Hansen, B. E., van der Laan, L. J. W., Polak, W. G., Kwekkeboom, J., van Schaik, R. H. N., van Gelder, T., et al. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000063 · Cited by 10

Treating mood disorders in patients with a history of intestinal surgery

Lloret‐Linares, C., Bellivier, F., Heron, K., & Besson, M. J. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000071 · Cited by 10

An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation

Keown, P. A., KIBERD, B. A., Balshaw, R. F., Khorasheh, S., Marra, C. A., BELITSKY, P., & Kaló, Z. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422100-00001 · Cited by 9

Determination of Appropriate Dosing of Influenza Drugs in Pediatric Patients

Acosta, E. P., & Kimberlin, D. W. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.173 · Cited by 7

Molecular cloning and expression analysis of cytochrome P450 3A gene in the turbot Scophthalmus maximus

Sun, A., Li, J., Huang, J., Chang, Z., Li, J., & Wang, Q. (2013) · Fish Physiology and Biochemistry · doi:10.1007/s10695-013-9779-5 · Cited by 7

Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole

Miura, M., Kagaya, H., Tada, H., Uno, T., Yasui‐Furukori, N., Tateishi, T., & Suzuki, T. (2006) · Xenobiotica · doi:10.1080/00498250500485065 · Cited by 7

Role of P-Glycoprotein and the Intestine in the Excretion of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in Rodents

Garner, C. E., Solon, E. G., Lai, C., Lin, J., Luo, G., Jones, K., Duan, J., Decicco, C. P., Maduskuie, T. P., Mercer, S. E., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017038 · Cited by 7

Drug Metabolism and Chronic Kidney Disease

Dreisbach, A. W., & Flessner, M. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00055-x · Cited by 7

Mechanisms of Drug Interactions

Kashuba, A. D. M., & Bertino, J. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-025-4_2 · Cited by 7

Presystemic Elimination of Trichloroethylene in Rats Following Environmentally Relevant Oral Exposures

Liu, Y., Bartlett, M. G., White, C. A., Muralidhara, S., & Bruckner, J. V. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028100 · Cited by 6

Antifungal therapeutic drug monitoring: When, how, and why

Grau, S., & Luque, S. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.03.005 · Cited by 6

Effect of Ketoconazole on Lobeglitazone Pharmacokinetics in Korean Volunteers

Oh, E. S., Kim, C. O., Kim, K. H., Kim, Y. N., Kim, C., Lee, J. I., & Park, M. S. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.064 · Cited by 6

Modeling and Simulation of Pharmacokinetic Aspects of Cytochrome P450-Based Metabolic Drug–Drug Interactions

Dickins, M., Galetin, A., & Proctor, N. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00152-8 · Cited by 4

PEDIATRIC PHARMACOLOGY

Neville, K. A., Blake, M. J., Reed, M. D., & Kearns, G. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50021-4 · Cited by 4

Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation

Cao, D., Qian, X., Wang, P., Zheng, X., Huang, S., Wei, Z., Jiang, W., Yu, L., Jiang, X., Yu, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1632588 · Cited by 3

SPURIOUS OBSERVATION OF SPLENIC CYP2B1 EXPRESSION

Sharma, M. R., Periandythevar, P., & Shapiro, B. H. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.9.1074 · Cited by 3

Transfert des polluants organiques persistants (POP) du fourrage vers le lait chez le ruminant

Pastor, A. C. (2007) · doi:10.70675/55e85633zcbe2z4394zbfa0z026839423968 · Cited by 3

Biomechanics for Pathology and Treatment

(2018) · Elsevier eBooks · doi:10.1016/b978-0-323-38944-0.00004-8 · Cited by 2

Drug Interactions in Solid Organ Transplant Recipients

Manitpisitkul, W., Wilson, N. S., Lee, S., & Weir, M. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0342-9_34 · Cited by 2

Antifungal Drug Interactions

Lewis, R. E. (2014) · ASM Press eBooks · doi:10.1128/9781555815523.ch33 · Cited by 2

Influence of intestinal microbiota on the metabolism of main cardiotropic drugs

Stepanov, M. S. (2024) · Perm Medical Journal · doi:10.17816/pmj41554-65 · Cited by 1

Stereoselective Renal Elimination

Brett, C., Ott, R. J., & Giacomini, K. (2003) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-55842-9_15

Human Oral Bioavailability Prediction of Four Kinds of Drugs

Yan, A., Wang, Z., Li, J., & Meng, M. (2012) · International Journal of Computational Models and Algorithms in Medicine · doi:10.4018/ijcmam.2012100104 · Cited by 1

Impact of intestinal metabolism on drug development

Mizuma, T. (2009) · Folia Pharmacologica Japonica · doi:10.1254/fpj.134.142 · Cited by 1

Abstracts of Symposium Presentations (Monday)

(2001) · Drug Metabolism Reviews · doi:10.1081/dmr-100106270

Abstracts of Symposium Presentations (Thursday)

(2001) · Drug Metabolism Reviews · doi:10.1081/dmr-100106329

Abstracts of Symposium Presentations (Tuesday)

(2001) · Drug Metabolism Reviews · doi:10.1081/dmr-100106289

Abstracts of Symposium Presentations (Wednesday)

(2001) · Drug Metabolism Reviews · doi:10.1081/dmr-100106303

First-pass metabolism.

Brodie, M. J. (1983) · PubMed · Cited by 20